Conference Track

Highlight on Special Hepatic Issues and Populations

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Interim Analysis: Peginterferon alfa-2b Maintenance Therapy May Reduce Incidence of HCV-Related HCC, Cirrhosis Complications
FibroScan Able to Determine Liver Fibrosis Stage in Patients With Histologic Evidence of NAFLD
Human Albumin Safe and Effective for Treatment of Hyponatremia in Cirrhotic Patients With Refractory Ascites
Study Suggests Depletion of CD4+CD25+ Regulatory T Cells Dramatically Improves Antitumor Immunity Induced by NY-ESO-1b Peptide Vaccine
Rosiglitazone Appears Superior to Metformin at Improving Metabolic Control and Liver Histology in Patients With NAFLD
Liver Stiffness Measurement Can Identify Clinically Significant and Severe Portal Hypertension in Patients With HCV-Related Cirrhosis
Radiologic Imaging Accurately Identifies Hypervascular Lesions With, but not Without, Washout in Cirrhotic Individuals Awaiting Liver Transplantation
Improved Survival for Acute Liver Failure Patients After 1996 due to Fewer HBV Cases and Earlier Admission to ICU
Nomograms Developed From Patient and Viral Data From the REVEAL Study Predict Risk for HCC in Chronically HBV–Infected Patients
Radiologic Staging of HCC Highly Correlated With Milan and USCF Criteria in Cirrhotic Patients Waiting for Liver Transplantation
No Difference in Short-term Bleeding-Related Complications and Mortality With Recombinant Factor VIIa Treatment vs Placebo in Cirrhotic Patients With Active Variceal Bleeding
Peginterferon alfa-2b Plus Ribavirin Therapy Slows Progression of Fibrosis in HCV Patients After Receiving Liver Transplantation
Long-term Treatment With V2 Receptor Antagonist Satavaptan Effective for Managing Hyponatremia in Patients With Cirrhosis
Magnetic Resonance Elastography Noninvasive Diagnostic Tool for Hepatic Fibrosis
Combination of Baseline Bilirubin, ALP, and AST Effective Biochemical Predictor of UDCA Therapy Response for Primary Biliary Cirrhosis

Expert Analysis

Highlight on Special Hepatic Issues and Populations

Faculty:

Nezam H. Afdhal, MD, FRCPI
Kris V. Kowdley, MD, FACP
Josep M. Llovet, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss treatment strategies for hyponatremia patients with cirrhosis and ascites
Recall data from studies investigating the treatment and prevention of hepatocellular carcinoma
Summarize findings from studies evaluating the accuracy of radiologic staging and imaging of hepatocellular carcinoma
Describe results from studies investigating the optimal time to initiate interferon-based therapy in liver transplant recipients with hepatitis C virus recurrence
Explain outcomes of studies investigating the use of insulin-sensitizing agents in the treatment of patients with fatty liver disease

CREDIT INFORMATION

Release Date: June 19, 2007

Expiration Date: June 18, 2008

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.3 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.